

## Claims:

1. New peptide, selected from the group that consists of

DVFMKGLSMAKEGV

VFMKGLSMAKEGV

FMKGLSMAKEGV

MKGLSMAKEGV

KGLSMAKEGV

GLSMAKEGV

LSMAKEGV

SMAKEGV

MAKEGV

AKEGV

KEGV

MDVFMKGLSMAKEG

MDVFMKGLSMAKE

MDVFMKGLSMAK

MDVFMKGLSMA

MDVFMKGLSM

MDVFMKGLS

MDVFMKGL

MDVFMKG

MDVFMK

MDVFM

MDVF

DVFMKGLSMAKEG

DVFMKGLSMAKE

DVFMKGLSMAK

DVFMKGLSMA

DVFMKGLSM

DVFMKGLS

DVFMKGL

DVFMKG

DVFMK

DVFM

DVF

GLSMAKEG

GLSMAKE

GLSMAK

GLSMA

GLSM

GLS

GL

LSMAKEG

LSMAKE

LSMAK

LSMA

LSM

LS.

2. Peptides according to claim 1, whereby the individual components are L-amino acids.
3. Peptides according to claim 1, whereby the individual amino acids are D-amino acids.
4. Peptides according to claim 1 or 2, in which the amino acid proline is substituted in the N-terminal position.
5. Peptides according to claim 1 or 2, in which the amino acid proline is substituted in the C-terminal position.

6. Peptides according to claim 1 or 2, in which the amino acid proline is substituted in the N-terminal position and in the C-terminal position.

7. Peptides according to one of claims 1 to 6, which are acetylated in the N-terminal position.

8. Peptides according to one of claims 1 to 7, which are amidated in the C-terminal position.

9. Peptides according to claim 7 or 8, which are acetylated in the N-terminal position and amidated in the C-terminal position.

10. Peptides according to one of claims 1 to 9, characterized in that the amino acid valine (V) is replaced by the amino acid proline (P).

11. Pharmaceutical agent for use in the therapy of diseases in which the increased occurrence of free radicals plays a pathophysiological role, characterized by at least one peptide according to one of claims 1 to 10.


12. Pharmaceutical agent for use in the therapy of diseases with acute hypoxia or ischemia in an organ system of the body, in particular in the central nervous system, characterized by at least one peptide according to one of claims 1 to 10.

13. Pharmaceutical agent for use in the therapy of Recklinghausen-Appelbaum diseases, such as the Hallervorden-Spatz disease, characterized by at least one peptide according to one of claims 1 to 10.

14. Pharmaceutical agent for use in the therapy of neurodegenerative diseases, in particular Alzheimer's disease, the Lewy Body variant of Alzheimer's disease, Parkinson's disease, the multisystem atrophy, the Lewy Body dementia or Huntington's chorea, and all states similar to these neurodegenerative diseases, characterized by at least one peptide according to one of claims 1 to 10 as an active ingredient.

15. Pharmaceutical agent according to one of claims 11 to 14, which is prepared for oral administration.

16. Pharmaceutical agent according to one of claims 11 to 14, which is prepared for rectal administration.



17. Pharmaceutical agent according to one of claims 11 to 14, which is prepared for administration by inhalation.
18. Pharmaceutical agent according to one of claims 11 to 14, which is prepared for transdermal administration.
19. Pharmaceutical agent according to one of claims 11 to 14, which is prepared for transmucosal administration.
20. Pharmaceutical agent according to one of claims 11 to 14, which is prepared for administration via active ingredient-containing implants.
21. Pharmaceutical agent according to one of claims 11 to 14, which is prepared for intracerebroventricular administration.
22. Pharmaceutical agent according to one of claims 11 to 14, which is prepared for administration by injection.
23. Pharmaceutical agent according to one of claims 11 to 14, which is prepared for transnasal administration.
24. Pharmaceutical agent according to one of claims 11 to 14, which is prepared for administration by infusion.
25. Use of at least one peptide according to claims 1 to 9 for the production of a pharmaceutical agent according to one of claims 11 to 14.
26. Use according to claim 25 for the production of a pharmaceutical agent according to claims 11 to 24.